10Suppliers
4Customers
3Debt Items
20Related Chains

Source-Backed Evidence Depth

Tempest Therapeutics, Inc. (TPST) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

18Total relationships
4Distinct source URLs
10High confidence
0.816Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Tempest Therapeutics, Inc. Suppliers

TickerNameConfidenceEvidence
ERIGEN ERIGEN 92% On February 3, 2026, the Company completed the acquisition of the Erigen Assets (the 'Erigen Closing') under the Asset Purchase Agreement (the 'Asset Acquisition') and issued to Erigen 8,268,495 shar…
FACTOR-BIOSCIENCE-LIMITED FACTOR-BIOSCIENCE-LIMITED 92% We are obligated to pay Factor Bioscience Limited up to $40 million in total upon achievement of certain development milestones for the programs.
H-C-WAINWRIGHT-CO-LLC H-C-WAINWRIGHT-CO-LLC 92% Pursuant to an engagement letter, H.C. Wainwright & Co., LLC (the “ Placement Agent ”) acted as the exclusive placement agent in connection with the foregoing transaction, and the Company issued to t…
NOVATIM NOVATIM 92% We are obligated to pay Novatim up to $80 million in total upon achievement of certain development milestones for the programs and up to $1.24 billion in total upon achievement of certain commercial …
FACTOR FACTOR 85% Pursuant to the Asset Purchase Agreement, Factor has made a funding commitment (the 'Funding Commitment') to provide the Company
COMPUTERSHARE-TRUST-COMPANY-NA COMPUTERSHARE-TRUST-COMPANY-NA 80% The descriptions and terms of the Rights are set forth in a Rights Agreement, dated as of October 10, 2023 (the 'Rights Agreement'), between the Company and Computershare Trust Company, NA.
CMOS CMOS 75% We enter into contracts in the normal course of business with equipment and reagent vendors, CROs, CMOs and other third parties for clinical trials, preclinical research studies and testing and manuf…
CROS CROS 75% We enter into contracts in the normal course of business with equipment and reagent vendors, CROs, CMOs and other third parties for clinical trials, preclinical research studies and testing and manuf…
EQUIPMENT-AND-REAGENT-VENDORS EQUIPMENT-AND-REAGENT-VENDORS 75% We enter into contracts in the normal course of business with equipment and reagent vendors, CROs, CMOs and other third parties for clinical trials, preclinical research studies and testing and manuf…
BDRX Biodexa Pharmaceuticals Plc 72% Reciprocal relationship from BDRX graph: Reciprocal relationship from TPST graph: Reciprocal relationship from BDRX graph: Reciprocal relationship from TPST graph: Reciprocal relationship from BDRX g…

Tempest Therapeutics, Inc. Customers

TickerNameConfidenceEvidence
BDRX Biodexa Pharmaceuticals Plc 72% Reciprocal relationship from BDRX graph: Reciprocal relationship from TPST graph: Reciprocal relationship from BDRX graph: Reciprocal relationship from TPST graph: Reciprocal relationship from BDRX g…
MYGN Myriad Genetics, Inc. 72% cting biopharmaceutical companies, and U.S. laws and regulations affecting biopharmaceutical companies based in or operating in China are also unpredictable. Any regulatory changes and changes in Uni…
MYGN Myriad Genetics, Inc. 72% Reciprocal relationship from MYGN graph: Reciprocal relationship from TPST graph: cting biopharmaceutical companies, and U.S. laws and regulations affecting biopharmaceutical companies based in or op…
MILLENDO-THERAPEUTICS-INC MILLENDO-THERAPEUTICS-INC 62% The risks we face in connection with acquisitions, include: • diversion of management time and focus from operating our business to addressing acquisition integration challenges; • coordination of re…

Tempest Therapeutics, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
TPST-DEBT Debt stack $199,000 90% Market cache reports total debt of $199,000.
TPST-DEBT-13083 Warrants outstanding: 6784989 90% xbrl warrant detail from xbrl 2026-02-03.
TPST-DEBT-13084 Xbrl Convertible 90% xbrl convertible detail from xbrl 2022-12-31.

Tempest Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Tempest Therapeutics, Inc..

Tempest Therapeutics, Inc. Ownership

HolderNameConfidenceEvidence
TPST-OWNER-VERSANT-VENTURE-MANAGEMENT-LLC Versant Venture Management, LLC 90% 13F overlay lists Versant Venture Management, LLC as top holder; 1 tracked holders.

Tempest Therapeutics, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
GSK GSK plc 100.00 2
GH Guardant Health, Inc. 100.00 2
BIAF bioAffinity Technologies, Inc. 100.00 2
COGT Cogent Biosciences, Inc. 100.00 2
PSNL Personalis, Inc. 100.00 2
HOWL Werewolf Therapeutics, Inc. 100.00 2
BIOA BioAge Labs, Inc. 100.00 2
ATYR aTyr Pharma, Inc. 100.00 2
ALLO Allogene Therapeutics, Inc. 100.00 2
BDRX Biodexa Pharmaceuticals Plc 100.00 1 ['customer', 'supplier']
DSGN Design Therapeutics, Inc. 100.00 2
IMNM Immunome, Inc. 100.00 2
BNBX BNB Plus Corp. 100.00 2
CABA Cabaletta Bio, Inc. 100.00 2
SDGR Schrödinger, Inc. 100.00 2
BNTC Benitec Biopharma Inc. 100.00 2
CALC CalciMedica, Inc. 100.00 2
ELVN Enliven Therapeutics, Inc. 100.00 2
CRSP CRISPR Therapeutics AG 100.00 2
KDK Kodiak AI, Inc. 100.00 2
🔐
TPST
Unlock TPST Supply Chain Data
Verified relationships include:
ERIGENERIGENSupplier92%
FACTOR-BIOSCIENCE-LIMITEDFACTOR-BIOSCIENCE-LIMITEDSupplier92%
BDRXBiodexa Pharmaceuticals PlcCustomer72%
MYGNMyriad Genetics, Inc.Customer72%
+14 more relationships locked
Subscribe, View plans →